Michael Combs is a Respiratory physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 5 Feb 2020.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
- SANOFI-AVENTIS U.S. LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
40.1%Short-acting sulfonamides16.6%Sulfamethoxazole-Trimethoprim100%Part D≥15 patientsMacrolide Antimicrobial15.5%Azithromycin100%Part D≥11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
24.8%Corticosteroid10.6%Prednisone100%Part D≥12 patientsProton pump inhibitor8.2%Omeprazole100%Part D<11 patients+ 1 more class in this area
Respiratory
17.7%beta2-Adrenergic Agonist6%Albuterol Sulfate Hfa100%Part D<11 patientsLeukotriene Receptor Antagonist5.4%Montelukast Sodium100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2025 per NIH RePORTER. The latest:
- Advancing our Understanding of the Development, Phenotypes, and Progression of Chronic Rejection after Lung Transplantation
University of Michigan at Ann Arbor
FY2025$196,193K23HL171904 - Advancing our Understanding of the Development, Phenotypes, and Progression of Chronic Rejection after Lung Transplantation
University of Michigan at Ann Arbor
FY2024$195,826K23HL171904
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”